What We Know about the Long-Term Risks of Hysterectomy for Benign Indication-A Systematic Review
- PMID: 34830617
- PMCID: PMC8622061
- DOI: 10.3390/jcm10225335
What We Know about the Long-Term Risks of Hysterectomy for Benign Indication-A Systematic Review
Abstract
Hysterectomy is the most common treatment option in women with uterine fibroids, providing definitive relief from the associated burdensome symptoms. As with all surgical interventions, hysterectomy is associated with risk of complications, short-term morbidities, and mortality, all of which have been described previously. However, information on the potential long-term risks of hysterectomy is only recently becoming available. A systematic literature review was performed to identify studies published between 2005 and December 2020 evaluating the long-term impact of hysterectomy on patient outcomes. A total of 29 relevant studies were identified. A review of the articles showed that hysterectomy may increase the risk of cardiovascular events, certain cancers, the need for further surgery, early ovarian failure and menopause, depression, and other outcomes. It is important to acknowledge that the available studies examine possible associations and hypotheses rather than causality, and there is a need to establish higher quality studies to truly evaluate the long-term consequences of hysterectomy. However, it is of value to consider these findings when discussing the benefits and risks of all treatment options with patients with uterine fibroids to allow for preference-based choices to be made in a shared decision-making process. This is key to ensuring that patients receive the treatment that best meets their individual needs.
Keywords: adverse events; complications; long-term consequences of hysterectomy; patient engagement; uterine fibroid management; uterine fibroids.
Conflict of interest statement
Obianuju Sandra Madueke-Laveaux is a consultant for CooperSurgical, Inc. Ayman Al-Hendy has provided consulting services to AbbVie, Bayer, Myovant, Novartis, and ObsEva, and he is grant funded by the National Institute of Health for fibroid-related research (R01 ES 028615-01, R01 HD 087417, R01 HD 094378, R01 HD 094380, 5U54 MD 007602-32, R01 HD 100367). In addition, he holds a patent for Methods for novel diagnostics and therapeutics for uterine sarcoma (US Pat No. 9,790,562 B2). Amro Elsharoud declares no conflict of interest.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
